Lauxera Capital Partners is an international investment firm based in Paris and San Francisco that focuses exclusively on healthcare and healthtech growth opportunities. Founded in 2020, the firm has quickly established itself as one of Europe’s most dynamic and hands-on investors in the healthcare technology sector. With a mission to transform Europe’s most promising healthtech pioneers into global market leaders, Lauxera combines operational expertise, transatlantic reach, and deep industry knowledge.
A Focus on Healthtech Growth
Lauxera Capital Partners specialises in growth-stage investments within the healthtech and life sciences sectors. The firm targets companies that have already developed proven technologies and are ready to scale commercially. By providing both capital and operational support, Lauxera helps founders accelerate international expansion and build globally competitive businesses.
Founders and Leadership
The firm was co-founded by Samuel Levy, a physician-turned-entrepreneur; Pierre Moustial, a veteran pharmaceutical executive and former CEO; and Alex Slack, an experienced healthcare investment professional. Together, they bring a unique blend of medical, operational, and financial expertise that spans both the European and American markets.
Pierre Moustial, Co-Founding Partner, explains that Lauxera’s strength lies in its cross-Atlantic perspective:
“We aim to bridge Europe and the U.S. to help impactful healthtech companies scale globally. Our investors’ confidence and the success of our portfolio companies demonstrate the strength of this vision.”
Lauxera Growth II: A Record-Breaking Fund
In 2025, Lauxera announced the successful close of Lauxera Growth II, its second Healthtech Growth Fund, which raised over €400 million. This achievement came in record time despite challenging market conditions, highlighting the strong trust investors place in Lauxera’s strategy and track record. The fund’s goal is to invest in late-stage European healthtech firms that are poised for global expansion.
Lauxera Growth II builds on the success of the firm’s debut fund, Lauxera Growth I, which supported several transformative companies in the healthtech space. The firm reviews over 1,000 opportunities annually, ensuring that each investment aligns with its mission to scale companies that make meaningful contributions to healthcare innovation.
Key Investments and Portfolio Highlights
Lauxera has built a diverse and impactful portfolio across medical devices, digital health, and AI-driven technologies. Among its most notable recent investments are:
- Acandis (Germany): A leading developer of neurovascular devices for stroke and aneurysm treatment. Lauxera invested €50 million to support the company’s international expansion and manufacturing footprint across more than 60 countries.
- Antaros Medical (Sweden): A company pioneering AI-powered imaging technology to improve the efficiency and precision of clinical trials in therapeutic areas such as obesity and immunology.
Previous investments under Lauxera Growth I include OrganOx, a medical technology company focused on organ preservation. OrganOx was acquired by Japan’s Terumo Group in August 2025 for $1.5 billion, marking one of the most successful exits in European healthtech.
Other portfolio companies include Natural Cycles, the world’s first FDA-approved non-hormonal contraception app, and several undisclosed healthtech firms working on digital diagnostics and next-generation medical devices.
A Hands-On Investment Approach
Unlike traditional European private equity firms, Lauxera takes an operationally engaged approach to investing. Its team works closely with portfolio companies to provide strategic and commercial guidance, especially in navigating complex U.S. regulatory frameworks and expanding into new markets. This hands-on model has become a defining characteristic of the firm and a major reason for its rapid success.
The firm’s dual presence in Paris and San Francisco allows it to connect European innovation with American market access. This transatlantic bridge helps portfolio companies gain faster regulatory approvals, expand sales networks, and attract additional growth capital.
Investing in the Future of Healthcare
Lauxera Capital Partners is committed to identifying and supporting the next generation of healthcare innovators. The firm’s investments span a broad range of high-growth sectors, including:
- AI-driven diagnostics and precision medicine
- Digital health and telemedicine platforms
- Advanced medical devices and implants
- Biotech and data-driven clinical research tools
Lauxera’s forward-looking investment philosophy aims to accelerate the transition of healthcare towards more efficient, data-centric, and patient-oriented solutions.
A Proven Track Record of Impact
Since its founding, Lauxera has rapidly built credibility as one of Europe’s leading healthtech investment firms. Its early success stories demonstrate an ability to identify promising innovations and transform them into globally competitive enterprises. The acquisition of OrganOx and the growth of companies like Acandis and Antaros Medical illustrate Lauxera’s effectiveness in driving both commercial success and clinical impact.
What Sets Lauxera Apart
Lauxera stands out for its deep operational involvement, transatlantic reach, and healthcare-specialised expertise. While many investors focus on financial engineering, Lauxera’s team works side by side with founders to address strategic, regulatory, and operational challenges. This partnership-based model helps bridge the gap between innovation and market adoption.
The Road Ahead
With over €400 million in its latest fund and a growing global footprint, Lauxera Capital Partners is positioned for continued expansion. The firm plans to announce a third major investment under its Growth II fund soon and remains open to new investors seeking exposure to high-impact healthcare technologies.
By connecting Europe’s healthtech innovators with the resources, capital, and expertise needed to compete globally, Lauxera is helping shape the future of healthcare on both sides of the Atlantic.
FAQs
What is Lauxera Capital Partners? Lauxera Capital Partners is an international investment firm based in Paris and San Francisco that focuses on growth-stage investments in the healthcare and healthtech sectors.
Who founded Lauxera Capital Partners? The firm was founded in 2020 by Samuel Levy, Pierre Moustial, and Alex Slack.
How much funding has Lauxera raised? Lauxera recently closed its second Healthtech Growth Fund, raising over €400 million.
What are some of Lauxera’s key investments? Recent investments include Acandis, Antaros Medical, OrganOx, and Natural Cycles.
What makes Lauxera unique? Lauxera differentiates itself through hands-on operational support, a transatlantic presence, and a deep focus on scaling European healthtech companies globally.
Final Thoughts
Lauxera Capital Partners has quickly become one of the most respected names in European healthtech investment. By pairing financial backing with real-world operational expertise, the firm empowers healthcare innovators to scale faster and reach more patients worldwide. Its strong leadership, proven results, and commitment to impactful innovation make Lauxera a cornerstone of the global healthtech investment landscape.